Get the Stockscreener App
190.11
0.55%
1.04
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $190.11, with a volume of 170.88K.
It is up +0.55% in the last 24 hours and down -2.56% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$189.07
Open:
$188.6
24h Volume:
170.88K
Relative Volume:
0.89
Market Cap:
$3.74B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
75.74
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
-2.92%
1M Performance:
-2.56%
6M Performance:
+67.26%
1Y Performance:
+75.35%
1-Day Range:
$186.47
$192.48
1-Week Range:
$186.47
$196.04
52-Week Range:
$93.58
$212.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
190.11 | 3.72B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Moody Aldrich Partners LLC Buys Shares of 25,884 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Calamos Advisors LLC Grows Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Book value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView — Track All Markets
Ligand Pharmaceuticals Earnings Notes - Trefis
Loss Report: How Ligand Pharmaceuticals Incorporated stock reacts to bond yieldsTrade Analysis Report & Daily Market Momentum Tracking - moha.gov.vn
Ligand Pharmaceuticals Incorporated $LGND Position Trimmed by Rice Hall James & Associates LLC - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY 2025 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals (LGND) Price Target Increased by 24.57% to 232.69 - MSN
Ligand Pharmaceuticals IncorporatedEquity Right (LGNDZ) Price Target Increased by 23.15% to 0.01 - Nasdaq
Ligand Pharmaceuticals Incorporated $LGND Stock Holdings Increased by Congress Asset Management Co. - MarketBeat
Published on: 2025-12-20 22:34:37 - Улправда
Will Ligand Pharmaceuticals Incorporated stock continue upward momentum2025 Earnings Impact & Community Consensus Stock Picks - Улправда
Can Ligand Pharmaceuticals Incorporated stock rebound after recent weaknessEarnings Performance Report & Free Verified High Yield Trade Plans - Улправда
How sustainable is Ligand Pharmaceuticals Incorporated stock dividend payoutJuly 2025 Action & Low Volatility Stock Recommendations - Улправда
Is Ligand Pharmaceuticals Incorporated stock positioned well for digital economyMarket Sentiment Report & Growth Focused Stock Pick Reports - DonanımHaber
Octavio Espinoza At Ligand Pharmaceuticals Capitalizes: Options Exercised, Resulting In $308K - Benzinga
Ligand Pharmaceuticals backs Athira Pharmas 90 million funding round - Traders Union
Will Ligand Pharmaceuticals Incorporated stock deliver better than expected guidance2025 Growth vs Value & Weekly High Conviction Ideas - Улправда
[Form 4] LIGAND PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Published on: 2025-12-19 00:15:21 - Улправда
Why Ligand Pharmaceuticals Incorporated stock could outperform in 2025July 2025 Technicals & Proven Capital Preservation Methods - Улправда
Gains Recap: Will Ligand Pharmaceuticals Incorporated stock continue upward momentum2025 Trading Volume Trends & Safe Capital Investment Plans - Улправда
Ligand Pharmaceuticals (NASDAQ: LGND) outlines Athira investment update and disclosure channels - Stock Titan
Woodstock Corp Sells 9,472 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
FY2026 Earnings Forecast for LGND Issued By Zacks Small Cap - MarketBeat
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? - Yahoo Finance
LIGAND PHARMACEUTICALS CFO Sells Shares - TradingView — Track All Markets
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells $339,711.24 in Stock - MarketBeat
LGND: 2025 Analyst Day - Zacks Small Cap Research
Ligand Pharmaceuticals Incorporated $LGND Stock Holdings Raised by Ranger Investment Management L.P. - MarketBeat
Market Leaders: Is Ligand Pharmaceuticals Incorporated stock safe for conservative investorsPortfolio Gains Summary & Free Technical Confirmation Trade Alerts - moha.gov.vn
CFO Espinoza Files To Sell 1,804 Of Ligand Pharmaceuticals Inc [LGND] - TradingView — Track All Markets
What is HC Wainwright's Forecast for LGND FY2026 Earnings? - MarketBeat
RBC Capital Maintains Ligand Pharmaceuticals IncorporatedEquity Right (LGNDZ) Outperform Recommendation - Nasdaq
Norges Bank Acquires Shares of 14,073 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
RBC Capital Maintains Ligand Pharmaceuticals (LGND) Outperform Recommendation - Nasdaq
Stifel Maintains Ligand Pharmaceuticals IncorporatedEquity Right (LGNYZ) Buy Recommendation - Nasdaq
Benchmark reaffirms Buy rating on Ligand Pharma stock with $220 target - Investing.com Canada
Oppenheimer reiterates Outperform rating on Ligand Pharma stock at $275 By Investing.com - Investing.com Canada
LGND: RBC Capital Raises Price Target, Maintains 'Outperform' Ra - GuruFocus
LGND: Stifel Raises Price Target to $230, Maintains 'Buy' Rating - GuruFocus
Stifel Nicolaus Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $230.00 - MarketBeat
RBC Lifts Price Target on Ligand Pharmaceuticals to $235 From $234, Keeps Outperform Rating - marketscreener.com
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance - 富途牛牛
CFO Espinoza Surrenders 1,862 Of Ligand Pharmaceuticals Inc [LGND] - TradingView — Track All Markets
Ligand Pharma stock price target raised to $230 by Stifel on growth outlook - Investing.com Canada
Citigroup Initiates Coverage of Ligand Pharmaceuticals (LGND) with Buy Recommendation - Nasdaq
LIGAND PHARMACEUTICALS INCINTRODUCES 2026 REVENUE GUIDANCE OF $245-$285 MLN - 富途牛牛
Citigroup Initiates Coverage On LGND with a Buy Rating | LGND St - GuruFocus
Ligand Pharma sets 2026 outlook as Citi starts at buy on valuation - MSN
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):